LisaOstroskySproatMDMSW

Clinical Director, Acute and Chronic Leukemia Program

Dr. Sproat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2006 - 2009
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Vermont College of MedicineClass of 2000

PubMed

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2024-12-13
Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide.
Anmol Baranwal, Kimberly J Langer, Mohamed A Kharfan-Dabaja, Ernesto Ayala, James Foran
Transplantation and Cellular Therapy. 2024-08-16
Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Mayo Clinic Clinical and Pathologic Study.
Sharad Khurana, Michael G Heckman, Fiona E Craig, Jordan J Cochuyt, Patricia Greipp
Archives of Pathology & Laboratory Medicine. 2024-04-01

Abstracts/Posters

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Ly...
Lisa Z. Sproat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019